Sat Kartar Shopping Ltd
Incorporated in June 2012, Sat Kartar Shopping Limited is an Ayurveda healthcare company that delivers natural wellness solutions for therapeutic and lifestyle products.[1]
- Market Cap ₹ 280 Cr.
- Current Price ₹ 178
- High / Low ₹ 178 / 146
- Stock P/E 45.2
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 98.3 %
- ROE 97.6 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| 52 | 83 | 128 | |
| 49 | 78 | 118 | |
| Operating Profit | 3 | 5 | 10 |
| OPM % | 5% | 6% | 8% |
| 0 | 0 | 0 | |
| Interest | 0 | 0 | 1 |
| Depreciation | 1 | 1 | 1 |
| Profit before tax | 2 | 3 | 9 |
| Tax % | 7% | 27% | 27% |
| 1 | 3 | 6 | |
| EPS in Rs | 1.99 | 3.59 | 22.54 |
| Dividend Payout % | 0% | 0% | 3% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 54% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 145% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 98% |
Balance Sheet
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Equity Capital | 0.70 | 0.70 | 3 |
| Reserves | 0 | 3 | 7 |
| 8 | 4 | 2 | |
| 3 | 8 | 11 | |
| Total Liabilities | 12 | 15 | 22 |
| 5 | 4 | 4 | |
| CWIP | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 |
| 8 | 11 | 18 | |
| Total Assets | 12 | 15 | 22 |
Cash Flows
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| 7 | |||
| -3 | |||
| -3 | |||
| Net Cash Flow | 2 |
Ratios
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Debtor Days | 1 | 0 | 7 |
| Inventory Days | 31 | 25 | 23 |
| Days Payable | 165 | 226 | 237 |
| Cash Conversion Cycle | -134 | -200 | -208 |
| Working Capital Days | 14 | -8 | -3 |
| ROCE % | 50% | 98% |
Documents
Announcements
No data available.
Annual reports
No data available.
Business Model[1]
The company operates in the Ayurveda healthcare sector using a Direct-to-Consumer (D2C) model, combining Ayurvedic principles with modern research. It focuses on product innovation, branding, and marketing while outsourcing manufacturing to trusted partners, adopting an asset-light strategy.